- ►diabetesjournals.org M Davies, F Storms, S Shutler, M Bianchi- … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—At baseline, mean diabetes duration was 12.3 ± 7.2 years, and 72% of
subjects were pretreated with insulin. At end point, there was no significant
difference in the incidence of severe hypoglycemia between algorithms 1 and ... Cited by 65 - Related articles - All 10 versions
V Fonseca, DS Bell, S Berger, S Thomson, … - The American journal of the medical sciences, 2004 - journals.lww.com ABSTRACT: Background: Basal insulin is frequently ad- ministered once daily.
This subgroup analysis of a multi- center, randomized, parallel study compared
insulin glargine (Lantus Aventis Pharmaceuticals, Bridgewater, NJ) with ... Cited by 44 - Related articles - BL Direct - All 3 versions
H Yki-Järvinen, R Kauppinen-Mäkelin, M … - Diabetologia, 2006 - Springer Page 1. Diabetologia (2006) 49: 442–451 DOI 10.1007/s00125-005-0132-0 ARTICLE H.
Yki-Järvinen . R. Kauppinen-Mäkelin . M. Tiikkainen . M. Vähätalo . ... Cited by 156 - Related articles - BL Direct - All 7 versions
FG Eliaschewitz, C Calvo, H Valbuena, M Ruiz … - Archives of medical research, 2006 - Elsevier Insulin glargine and NPH insulin achieved similar HbA 1c reductions (adjusted
mean difference −0.047; 90% CI −0.232, 0.138; per-protocol analysis).
Confirmed nocturnal hypoglycemia was significantly lower with insulin ... Cited by 27 - Related articles - All 3 versions
JK Malone, LF Kerr, BN Campaigne, RA … - Clinical therapeutics, 2004 - Elsevier One hundred five patients (mean age, 55 years) were randomized. There was no
difference in baseline mean values for either treatment sequence group for body
mass index, duration of DM, or HbA 1c . Ninety-five patients completed the ... Cited by 52 - Related articles - All 4 versions
- Free from Publisher H Yki-Järvinen, L Juurinen, M Alvarsson, T … - Diabetes Care, 2007 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A randomized (1:1), multicenter, two-arm, parallel
design study with a recruiting period of up to 14 weeks and a 24-week treatment
period. Either in groups of 4–8 or individually, using the same personnel ... Cited by 20 - Related articles - BL Direct - All 5 versions
- Free from Publisher J Rosenstock, G Dailey, M Massi-Benedetti, A … - Diabetes Care, 2005 - Am Diabetes Assoc OBJECTIVE—Insulin glargine (LANTUS) is a once-daily basal insulin analog with
a smooth 24-h time-action profile that provides effective glycemic control with
reduced hypoglycemia risk (particularly nocturnal) compared with NPH ... Cited by 196 - Related articles - All 6 versions
M Massi Benedetti, E Humburg, A Dressler, … - Hormone and metabolic research, 2003 - cat.inist.fr Aims: The aim of the trial was to compare the efficacy and safety of the new,
long-acting basal insulin, insulin glargine(LANTUS®), with NPH human
insulin, each administered in a combination regimen with oral antidiabetic ... Cited by 103 - Related articles - BL Direct - All 2 versions
L Meneghini, C Koenen, W Weng, JL Selam - Diabetes, Obesity & Metabolism, 2007 - pt.wkhealth.com The Predictable Results and Experience in Diabetes through Intensification and
Control to Target: An International Variability Evaluation 303 (PREDICTIVE™
303) Study (n = 5604) evaluated the effectiveness of insulin detemir, a ... Cited by 18 - Related articles - All 4 versions
HU Janka, G Plewe, MC Riddle, C Kliebe- … - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a 24-week, multinational, multicenter, open,
parallel group clinical trial, 371 insulin-naïve patients with poor glycemic
control (fasting blood glucose [FBG] ≥120 mg/dl, HbA 1c 7.5–10.5%) on ... Cited by 222 - Related articles - All 8 versions
